Martingale Asset Management L P Sells 4,090 Shares of Chemed Corporation $CHE

Martingale Asset Management L P lessened its stake in shares of Chemed Corporation (NYSE:CHE) by 14.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,042 shares of the company’s stock after selling 4,090 shares during the period. Martingale Asset Management L P’s holdings in Chemed were worth $14,794,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CHE. Alpine Bank Wealth Management bought a new position in Chemed in the 1st quarter worth $29,000. HM Payson & Co. bought a new stake in Chemed during the 1st quarter valued at approximately $30,000. Whipplewood Advisors LLC grew its stake in shares of Chemed by 54.5% in the first quarter. Whipplewood Advisors LLC now owns 51 shares of the company’s stock worth $31,000 after acquiring an additional 18 shares during the last quarter. Versant Capital Management Inc boosted its holdings in Chemed by 600.0% in the 1st quarter. Versant Capital Management Inc now owns 98 shares of the company’s stock valued at $60,000 after purchasing an additional 84 shares during the period. Finally, Zions Bancorporation National Association UT acquired a new stake in Chemed in the 1st quarter worth $68,000. 95.85% of the stock is owned by institutional investors.

Insider Transactions at Chemed

In other news, Director George J. Walsh III acquired 200 shares of the company’s stock in a transaction on Monday, August 4th. The stock was purchased at an average cost of $417.10 per share, with a total value of $83,420.00. Following the acquisition, the director owned 3,523 shares of the company’s stock, valued at $1,469,443.30. This trade represents a 6.02% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Nicholas Michael Westfall sold 10,012 shares of the company’s stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $421.91, for a total transaction of $4,224,162.92. The disclosure for this sale can be found here. 3.29% of the stock is owned by company insiders.

Chemed Stock Performance

Shares of CHE stock opened at $455.98 on Thursday. The stock’s fifty day moving average is $476.51 and its 200-day moving average is $542.28. Chemed Corporation has a 52 week low of $408.42 and a 52 week high of $623.60. The stock has a market capitalization of $6.64 billion, a PE ratio of 23.44, a PEG ratio of 2.50 and a beta of 0.46.

Chemed (NYSE:CHE) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $4.27 EPS for the quarter, missing analysts’ consensus estimates of $6.02 by ($1.75). Chemed had a return on equity of 25.83% and a net margin of 11.56%.The company had revenue of $618.80 million for the quarter, compared to the consensus estimate of $650.60 million. During the same period in the prior year, the company earned $5.47 EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, analysts forecast that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 29th. Investors of record on Monday, August 11th will be issued a $0.60 dividend. This is a positive change from Chemed’s previous quarterly dividend of $0.50. This represents a $2.40 annualized dividend and a yield of 0.5%. The ex-dividend date is Monday, August 11th. Chemed’s dividend payout ratio (DPR) is 12.34%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CHE shares. Wall Street Zen cut shares of Chemed from a “buy” rating to a “hold” rating in a research note on Saturday, July 5th. Bank of America lowered their price objective on Chemed from $708.00 to $650.00 and set a “buy” rating on the stock in a research report on Monday, June 30th. Jefferies Financial Group began coverage on shares of Chemed in a research note on Friday, July 25th. They set a “hold” rating and a $500.00 price target on the stock. Oppenheimer dropped their price objective on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Finally, Royal Bank Of Canada lowered their target price on shares of Chemed from $640.00 to $589.00 and set an “outperform” rating on the stock in a research note on Thursday, July 31st. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $579.75.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.